A Tiny Implant Could Finally Fix Sleep Apnea for People Who Hate Their CPAP Mask

.

The Problem With the "Gold Standard" Treatment

Continuous positive airway pressure, or CPAP, is still considered the most effective treatment for obstructive sleep apnea. A steady stream of pressurized air, delivered through a mask, keeps the throat from collapsing during sleep.

But there's a catch: a large share of patients can't stick with it. Across two decades of published research, roughly one in three people prescribed CPAP were found to be non-adherent, and some studies put the figure far higher depending on how adherence is measured. Common complaints include claustrophobia, a mask that doesn't fit well, dry mouth, or simply the discomfort of sleeping with a machine strapped to the face.

For these patients, doctors have increasingly turned to an alternative that skips the mask entirely.

.

How Hypoglossal Nerve Stimulation Works

The treatment is built around a small device, implanted under the skin of the chest, that connects to the hypoglossal nerve — the nerve that controls tongue movement. A sensing lead detects the effort of breathing, and the stimulator delivers electrical pulses to the nerve in sync with each breath, nudging the tongue forward so it can't fall back and block the airway.

Patients switch the device on before bed using a small remote and turn it off in the morning. There is no mask, no hose, and no machine on the nightstand.

The approach isn't experimental. The only version currently approved by the U.S. Food and Drug Administration is the Inspire device, which has three parts implanted in the neck and chest, and it has been in clinical use for more than a decade.

.

What the Research Shows

The strongest evidence comes from a long-running study known as the STAR trial, which has tracked patients for years after implantation.

At the 36-month mark, the average number of breathing interruptions per hour had dropped by 62 percent compared with before treatment, and about three-quarters of participants met the study's definition of a successful response. Daytime sleepiness improved sharply too: only a third of patients had normal alertness scores before the implant, compared with more than three-quarters three years later.

A separate 2026 study in the journal Chest, focused on a newer "proximal" version of the technology, found similarly durable results. Median breathing-disruption scores fell from about 36 events per hour at baseline to roughly 19 within the first year and remained near that level three years later — evidence that the benefit doesn't fade with time.

Bed partners notice a difference as well. In one trial of a related device, the share of bed partners reporting loud or very intense snoring — or leaving the bedroom because of it — fell from 96 percent before treatment to 35 percent afterward. A separate acoustic study measured the effect directly: average snoring loudness dropped from 42.9 to 36.4 decibels, and the time spent snoring each night fell from roughly 30 percent to 14 percent.

.

Who Is a Good Candidate — and Who Isn't

This is not a treatment doctors hand out casually. Current guidance limits it to patients with moderate to severe sleep apnea who have failed or cannot tolerate CPAP, and who have a body mass index of 32 or below.

Anatomy matters too. Surgeons typically use an endoscopy performed under light sedation to watch exactly how the airway collapses during simulated sleep, since certain collapse patterns respond far better to stimulation than others.

Weight remains a key variable even after implantation. A retrospective review of more than 200 patients found that obesity was linked to higher post-treatment breathing-disruption scores and to lower odds of meeting standard treatment-success criteria at six months. Some ear, nose, and throat specialists also caution that people who lose significant weight quickly on newer weight-loss drugs, and later regain it, may see their throat muscle tone deteriorate faster than expected — a factor increasingly discussed in sleep clinics, though not yet the subject of large published studies.

.

The Procedure and Recovery

Implantation is a same-day or next-day outpatient procedure. The surgery typically takes two to three hours, and patients usually go home the same day.

The device isn't switched on immediately. Surgeons activate it several weeks after implantation, and patients then spend the following months gradually increasing the stimulation level under medical supervision.

Complications are relatively uncommon. In an analysis of more than 20,000 implants, the rate of device removal within the first year was under 1 percent, and the rate of revision surgery was roughly 1.5 percent. Milder, temporary effects — tongue soreness, dry mouth, or minor discomfort from the stimulation — are more frequent but usually manageable.

.

Not a Cure-All on Its Own

Specialists are careful to frame the implant as one tool among several, not a standalone fix. Nasal breathing problems, throat muscle tone, and body weight can all independently affect how well the airway stays open at night, which is one reason outcomes vary between patients.

For some people, the best results come from combining the implant with weight management, positional therapy (avoiding sleeping on the back), a nasal treatment, or an oral appliance. A newer option has also emerged in recent years: in December 2024, the FDA separately approved the weight-loss drug tirzepatide specifically for treating obstructive sleep apnea in patients with obesity, based on trial data showing substantial reductions in breathing disruptions tied to weight loss.

Sleep apnea itself is widespread and often underdiagnosed. The condition affects an estimated 3 to 9 percent of the general population, and untreated cases are linked to long-term cardiovascular and metabolic risks — one more reason doctors say it's worth exploring every treatment option, not settling for a mask nobody wears.

.

Sources

1. New England Journal of Medicine — "Upper-Airway Stimulation for Obstructive Sleep Apnea" (STAR trial): https://www.nejm.org/doi/full/10.1056/NEJMoa1308659
2. PMC / National Library of Medicine — STAR trial 36-month outcomes summary: https://pmc.ncbi.nlm.nih.gov/articles/PMC5698546
3. Journal of Clinical Sleep Medicine — "Device-related outcomes following hypoglossal nerve stimulator implantation": https://jcsm.aasm.org/doi/10.5664/jcsm.11176
4. Respiratory Medicine (Elsevier, open access) — updated systematic review and meta-analysis of hypoglossal nerve stimulation: https://www.resmedjournal.com/article/S0954-6111(24)00301-9/fulltext
5. Johns Hopkins Medicine — patient guide to hypoglossal nerve stimulation implants: https://www.hopkinsmedicine.org/health/conditions-and-diseases/obstructive-sleep-apnea/hypoglossal-nerve-stimulation
6. PMC — retrospective outcomes review by comorbidity status: https://pmc.ncbi.nlm.nih.gov/articles/PMC13490707/
7. CHEST journal portfolio summary — three-year outcomes of proximal hypoglossal nerve stimulation (2026): https://www.chestphysician.org/top-reads-from-the-chest-journal-portfolio-may-2026/
8. PMC — systematic review on CPAP non-adherence rates (1994–2015): https://pmc.ncbi.nlm.nih.gov/articles/PMC4992257/

.